Aurobindo gets USFDA nod to market heart disease drug
Advertisement
NEW DELHI: Aurobindo Pharma has received US health regulator's approval to market Eptifibatide Injection, used in the treatment of acute coronary syndrome, in the American market.
The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Eptifibatide Injection, Aurobindo Pharma said in a filing to the BSE.
This product is expected to be launched in this month, it added.
The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Eptifibatide Injection, Aurobindo Pharma said in a filing to the BSE.
This product is expected to be launched in this month, it added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.